ルーシッド・ダイアグノスティクス
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.08 | $1M | -$11M |
| 2026 Q1 | -0.17 | $1M | -$12M |
| 2025 Q4 | -0.12 | $2M | -$13M |
| 2025 Q3 | -0.10 | $1M | -$11M |
| 2025 Q2 | -0.08 | $1M | -$11M |
| 2025 Q1 | -0.52 | $828,000 | -$13M |
| 2024 Q4 |
| -0.20 |
| $1M |
| -$10M |
| 2024 Q3 | -0.25 | $1M | -$11M |